Label: ORAL CITRATE SOLUTION- citric acid and sodium citrate solution

  • NDC Code(s): 71321-604-16
  • Packager: Brandywine Pharmaceuticals, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated February 19, 2024

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx Only

  • DESCRIPTION

    The product is a clear, colorless solution containing Citric Acid USP 640 mg/5 mL, and Hydrous Sodium Citrate USP 490 mg/5 mL. These concentrations yield 1 mEq of sodium, equivalent to 1 mEq of bicarbonate per mL of solution.

  • ACTION

    Oral citrate solution is used as a systemic and urinary alkalinizer. Less than 5% of the citrate is excreted in the urine unchanged, since citrate oxidation is to a great extent complete.

  • INDICATIONS

    Oral Citrate Solution is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long-term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). Oral Citrate Solution is also effective in treatment for acidosis of certain renal tubular disorders.

  • CONTRAINDICATIONS

    Oral Citrate Solution is contraindicated in patients with severe renal impairment, oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.

  • PRECAUTIONS

    The citrate solution should be used with caution in patients with impaired renal function to avoid hypernatremia or alkalosis in the presence of hypocalcemia. Periodic determinations of serum electrolyte levels (especially bicarbonate levels) should be done in patients with renal disease to avoid cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy. The solution should be diluted with water and preferably taken after meals to avoid saline laxative effects.

  • ADVERSE REACTIONS

    Citrate solution is generally well tolerated when given in recommended doses when the patient has normal renal functions. To report suspected adverse reactions, contact Brandywine Pharmaceuticals, LLC at 610-314-7943 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

  • DOSAGE AND ADMINISTRATION

    The dose of Oral Citrate Solution is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve the desired effects.

  • HOW SUPPLIED

    Oral Citrate Solution is supplied in a 473 mL bottle (NDC 71321-604-16).

    PHARMACIST

    Dispense in well-closed containers.

    Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].

  • SPL UNCLASSIFIED SECTION

    Brandywine Pharmaceuticals, LLC
    West Chester, PA USA
    Revised February 2024

  • PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

    Label

    NDC 71321-604-16
    473 mL

    ORAL CITRATE (SHOHL'S) SOLUTION

    CONTAINS: Hydrous Sodium Citrate USP 490 mg/5 mL;
    Citric Acid USP 640 mg/5 mL;

    grape flavor, purified water, sodium

    benzoate, sodium saccharin, sorbitol

    USUAL DOSAGE: See package insert.

    Dispense in a well-closed container.

    Store at 20°-25°C (68°-77°F); excursions permitted
    to 15°-30°C (59°-86°F). [See USP Controlled Room
    Temperature].

    GTIN: 00371321604162

    Rx Only

    Brandywine Pharmaceuticals, LLC

    West Chester, PA USA

  • INGREDIENTS AND APPEARANCE
    ORAL CITRATE SOLUTION 
    citric acid and sodium citrate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:71321-604
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID490 mg  in 5 mL
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID640 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SACCHARIN SODIUM (UNII: SB8ZUX40TY)  
    SORBITOL SOLUTION (UNII: 8KW3E207O2)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:71321-604-16473 mL in 1 BOTTLE; Type 0: Not a Combination Product02/21/2024
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other02/21/2024
    Labeler - Brandywine Pharmaceuticals, LLC (080581956)
    Establishment
    NameAddressID/FEIBusiness Operations
    Brandywine Pharmaceuticals, LLC080581956label(71321-604)